Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents | Zendy

AI Assistant Blog Pricing

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.